Business Context and Reporting Period
Anteris Technologies Global Corp. (AVR), an emerging growth company incorporated in Delaware with principal offices in Australia, filed this Form 8-K on May 22, 2026. The report details the entry into a material definitive agreement to facilitate an equity offering.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the terms of a new sales agreement.
- Offering Capacity: Up to $250,000,000 in aggregate offering price.
- Commission Rate: 3.0% of gross proceeds payable to the sales agent.
- Securities Type: Common Stock, par value $0.0001 per share.
Material Changes
On May 22, 2026, the Company entered into a Sales Agreement with TD Securities (USA) LLC ("TD Cowen"). This agreement establishes an "at-the-market" (ATM) facility allowing the Company to sell shares of its common stock through TD Cowen acting as agent or principal. The offering is conducted pursuant to an effective shelf registration statement on Form S-3 filed in January 2026.
Guidance, Outlook, and Risks
Use of Proceeds: The Company intends to use net proceeds primarily for the ongoing development of its DurAVR® Transcatheter Heart Valve System, with remaining funds allocated to working capital and general corporate purposes.
Termination and Risks:
- The Company cannot provide assurances that it will issue any shares under the agreement.
- Either party may terminate the agreement with ten days' prior notice.
- TD Cowen may terminate immediately upon a material adverse effect on the Company, failure to perform obligations, or suspension of trading on Nasdaq.
Investor Verification Checklist
- Verify the current market price of AVR stock to assess potential dilution impact from the $250 million ATM facility.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific price, time, or size limits the Company may impose.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.
- Confirm the status of the DurAVR® Transcatheter Heart Valve System development pipeline.